Nanoemulsions for “Nose-to-Brain” Drug Delivery
Open accessThe DOI matches its Crossref record; 84 of the 87 references it cites were found in a registry or an index; 59 of the 142 sources its claims cite were checked for support.
Abstract
The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic substances and therefore also controls and restricts the entry of therapeutic agents. The nasal administration of drugs using the nose-to-brain pathway allows direct drug targeting into the brain, avoiding the first-pass effect and bypassing the BBB. Through the nasal route, the drug can access the brain directly along the trigeminal and olfactory nerves, which are located in the upper part of the nasal cavity. Nanoemulsions are formulations belonging to the field of nanomedicine. They consist of emulsions (commonly oil in water) stabilized by one or more surfactants—and eventually co-surfactants—delivered in droplets of small dimensions (sizes of 100–300 nm or less) with a high surface area. A mucoadhesive polymer such as chitosan can be added to the formulation to impair rapid nasal clearance. Nanoemulsions represent promising formulations to deliver drugs directly into the brain through the intranasal route. Therefore, they can be used as a possible alternative to oral administration, avoiding problems such as low solubility in water, poor bioavailability, enzymatic degradation and slow onset of action. This review focuses the present situation in literature regarding the use of nanoemulsions for nose-to-brain targeting, with particular attention to recent publications. Nasal nanoemulsions appear to be effective, non-invasive and safe drug delivery systems to achieve brain targeting for the treatment of neurological diseases.
Overview
CoChat Summary
TL;DR
This review summarizes nanoemulsions (NEs) for nose-to-brain drug delivery, emphasizing oil-in-water systems with droplets around 100–300 nm, mucoadhesive chitosan, and intranasal bypass of the blood–brain barrier. It concludes that nasal NEs are promising, effective, non-invasive, and safe for brain targeting, but clinical studies are still needed.
Key findings
- NEs are O/W or W/O dispersions stabilized by surfactants, with mean droplet diameter about 100 nm and reported upper limits up to 300 nm; reviewed intranasal formulations are O/W, and chitosan is added as a mucoadhesive and penetration enhancer.
- The nose-to-brain route bypasses the BBB via olfactory and trigeminal nerves; nasal doses are often 2–10 times lower than oral doses, but about 98% of low-molecular-weight active substances and nearly 100% of macromolecules do not permeate the BBB (Pardridge 2005). The human olfactory region is 2–12.5 cm², about 1.25–10% of the nasal cavity surface, and about 60 μm thick.
- Across reviewed examples, intranasal NEs improved brain delivery versus nasal solutions, intravenous administration, or oral administration for drugs including risperidone, olanzapine, saquinavir, nimodipine, curcumin, resveratrol, cyclosporine-A, riluzole, selegiline, thymoquinone, paroxetine, quetiapine, zolmitriptan, rivastigmine, and kaempferol. Specific reported values include riluzole NEs with drop size about 24 nm, thymoquinone NEs with mean globule size about 100 nm, and paroxetine NEs with about threefold permeation enhancement versus suspension.
- Bioimaging showed that NEs of about 100 nm had prolonged nasal residence and were transported through trigeminal and olfactory nerves to the olfactory bulb, whereas larger NEs were cleared faster; particle size played a more important role than chitosan coating or thermosensitive in situ gel thickening.
Methods
- Narrative review of the literature on NEs for nose-to-brain targeting, with particular attention to recent publications; no systematic search strategy, inclusion/exclusion criteria, or meta-analysis is stated.
- Data are published studies and examples summarized by drug loaded and therapeutic purpose; Tables 1 and 2 are referenced but not included in the provided text.
- Main synthesis is qualitative, describing NE composition, excipients, preparation methods, and in vitro, ex vivo, and in vivo outcomes.
Limitations
- The paper states that clinical studies of these formulations are still needed to demonstrate their appropriateness in clinical practice; it also states that no data seem available on the relevance of oil choice for nasal and especially nose-to-brain administration, and that literature contains confusion in classifying NEs versus microemulsions.
- Evident from the text: this is a narrative review without systematic search or quantitative synthesis, and the referenced tables are not included in the provided text.
- Evident from the text: most cited evidence is preclinical, using ex vivo nasal mucosa and rodent models, with no detailed clinical trial results reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
49 Valid · 4 Not valid · 53 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, the highest possible solubility is required to decrease the amount of oil used, reducing the required amounts of surfactants that might determine toxicity problems [34].”
§ Nanoemulsions for “Nose-to-Brain” Drug Delivery > 2. General Characteristics of NEs in Brief
What the sources say
- Partly supportedcites [34] Mahmoud H. Al-Suwayeh S. Elkadi S. Design and optimization of self nanoemulsifying drug delivery systems of simvastatin aiming dissolution enhancement Afr. J. Pharm. Pharmacol. 2013 7 1482 1500 10.5897/AJPP2013.2987 sourceExperimental — accuracy not yet measured
The Solubility studies section says that an oil phase’s ability to dissolve the drug is a consideration in oil selection and reports testing simvastatin solubility in different oils (page not available). It does not say that higher solubility reduces the amount of oil or surfactant required, or discuss surfactant toxicity as the reason to do so. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite these limitations, examples of promising results are present in clinical trials [19,20].”
§ Nanoemulsions for “Nose-to-Brain” Drug Delivery > 1. Introduction
What the sources say
- Supportedcites [19] Quintana D.S. Westlye L.T. Rustan Ø.G. Tesli N. Poppy C.L. Smevik H. Tesli M. Røine M. Mahmoud R.A. Smerud K.T. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: A randomized four-way crossover trial with nasal cavity dimension assessment Transl. Psychiatry 2015 5 e602 10.1038/tp.2015.93 26171983 PMC5068727 source
The Discussion (page unavailable in our copy) describes a double-blind, placebo-controlled crossover trial in healthy volunteers. It reports that intranasal oxytocin delivered with a Breath Powered device changed a measure of social cognition while intravenous oxytocin did not, and interprets this as behavioral evidence of nose-to-brain delivery. That supports citing the trial as a promising example, without establishing clinical efficacy. (LLM, conf=0.90)
- Not matchedcites [20] Stützle M. Flamm J. Carle S. Schindowski K. Nose-to-brain delivery of insulin for Alzheimer’s disease Admet Dmpk. 2015 3 190 202 10.5599/admet.3.3.184
We searched by its title and found no matching paper.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“According to the present literature, different kinds of nanocarriers are used to prepare nasal formulations able to target the brain, constituted by polymer-based and lipid-based nanoparticles [21,22,23].”
§ Nanoemulsions for “Nose-to-Brain” Drug Delivery > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [21] Rassu G. Soddu E. Posadino A.M. Pintus G. Sarmento B. Giunchedi P. Gavini E. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy Colloids Surf. B Biointerfaces 2017 152 296 301 10.1016/j.colsurfb.2017.01.031 28126681 source
- Supportedcites [22] Sonvico F. Clementino A. Buttini F. Colombo G. Pescina S. Stanisçuaski Guterres S. Raffin Pohlmann A. Nicoli S. Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting Pharmaceutics 2018 10 34 10.3390/pharmaceutics10010034 29543755 PMC5874847 source
Section 1, “Pharmaceutical Nanotechnologies for Nose-to-Brain Delivery,” says that nanocarriers studied for nose-to-brain delivery include polymeric nanoparticles and lipid-based carriers such as solid lipid nanoparticles and nanostructured lipid carriers. This supports the cited sentence’s identification of both types as nasal formulation approaches for brain delivery. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [23] Rassu G. Gavini E. Carta A. Obinu A. Porcu E.P. Giunchedi P. Hydroxypropyl-β-Cyclodextrin Formulated in Nasal Chitosan Microspheres as Candidate Therapeutic Agent in Alzheimer’s Disease Curr. Drug Deliv. 2018 15 746 748 10.2174/1567201814666171019104509 29065835 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Significantly high ex vivo trans-nasal mucosal fluxes were found using a Franz diffusion cell on porcine nasal mucosa.”
§ Nanoemulsions for “Nose-to-Brain” Drug Delivery > 3. General Overview of NEs for Nose-to-Brain Delivery
What the sources say
- Supportedcites [58] Pangeni R. Sharma S. Mustafa G. Ali J. Baboota S. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress Nanotechnology 2014 25 485102 10.1088/0957-4484/25/48/485102 25392203 source
Section 2.8.5 describes testing resveratrol nanoemulsion on porcine nasal mucosa with a Franz diffusion cell. The Conclusion reports significantly high ex vivo trans-nasal mucosal flux, matching the attributed claim. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vivo studies carried out in rats demonstrated high plasma and brain concentrations of nimodipine in the case of NE formulations containing Carbopol 934 P.”
§ Nanoemulsions for “Nose-to-Brain” Drug Delivery > 3. General Overview of NEs for Nose-to-Brain Delivery
What the sources say
- Supportedcites [54] Pathak R. Dash R.P. Misra M. Nivsarkar M. Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route Acta Pharm. Sin. B 2014 4 151 160 10.1016/j.apsb.2014.02.002 26579378 PMC4590727 source
The Conclusions identify 0.3% Carbopol 934 P as part of the optimized mucoadhesive microemulsion and report higher brain and plasma nimodipine concentrations in rats than with the earlier formulation. The Results and discussion (Evaluation of formulation, Table 5) also show higher peak concentrations for the in situ gelling mucoadhesive microemulsion than for the other tested formulations. (LLM, conf=0.92)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
58 more claims · 15 with their cited sources checked
Create a free account to see all 137 claims and every source verdict.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 54
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nanoemulsions for “Nose-to-Brain” Drug Delivery > 3. General Overview of NEs for Nose-to-Brain Delivery
“In vivo pharmacokinetics studies were carried out in mice in comparison with intravenous and nasal solutions of zolmitriptan.”
§ Nanoemulsions for “Nose-to-Brain” Drug Delivery > 3. General Overview of NEs for Nose-to-Brain Delivery
“In vivo studies carried out on Sprague–Dawley rats showed that the mucoadhesive (chitosan containing) NE presents higher AUC and shorter Tmax in the brain than intravenous or the nasal solutions.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Ahmad N. Ahmad R. Alam M.A. Ahmad F.J. Amir M. Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy Artif. Cells Nanomed. Biotechnol. 2018 23 1 16 10.1080/21691401.2018.1489826 30032652”
Cited work 10.1080/21691401.2018.1489826 · retracted 2021-01-11 · notice 10.1080/21691401.2020.1842980 · this paper published 2019-02-17
Citations
Cites
1 retracted
Ahmad, N., Ahmad, R., Alam, M. A., Ahmad, F. J., & Amir, M. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1489826 · Cited by 46
RetractedDaneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 5×
“BECs are different from endothelial cells of non-neural tissues—they are polarized cells, held together by tight junctions that strongly limit the paracellular flux of solutes (molecules and ions) and restrict vesicle-mediated transcellular transports (pinocytosis/transcytosis) [1,2].”
BackgroundInfluentialThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Comprehension of the mechanisms that regulate the BBB during health and their modification during disease involve interdisciplinary studies that several researchers have put correctly into evidence and can give an important support to finding the correct therapeutic treatments for a wide series of neurological disorde…”
BackgroundNanoemulsions: Formation, properties and applications
Gupta, A., Eral, H. B., Hatton, T. A., & Doyle, P. S. (2016) · Soft Matter · doi:10.1039/c5sm02958a · Cited by 1,633
Nanoemulsion: Concepts, development and applications in drug delivery
Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.008 · Cited by 1,358 · cited 8×
“Usually the lipids used for the preparation of NEs, alone or in mixture, are fractions of oils of natural origin such as sesame oil, cottonseed oil, soybean oil, coconut oil, and so on that can be classified according to chain lengths as long-chain, medium-chain and short-chain triglycerides [29].”
BackgroundMethodInfluentialCurcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254 · cited 1×
“The curcumin oral administration in Alzheimer’s disease animal models determines the inhibition of Amiloid beta (Aβ) peptide oligomerization and deposition in the brain [56].”
BackgroundIntranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239 · cited 1×
“However, all of these techniques are very invasive and risky, in particular because of the need for surgical intervention [6], and many of them are not suitable in cases of multiple or chronic regimens.”
BackgroundDesign and production of nanoparticles formulated from nano-emulsion templates-A review
Anton, N., Benoit, J.-P., & Saulnier, P. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.02.007 · Cited by 1,226
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Research works printed but not linked: 1
- Niranjan P. Reddy A.V. Reddy G.V.S. Panda K.C. Formulation, design and in vitro evaluation of zolmitriptan immediate release tablets using Primojel and Ac-Di-Sol J. Pharm. Sci. Res. 2015 7 545 553
Cited by
Items 201–263 of 263
Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases
Kalita, R., Sarma, A., Baruah, H., Zaman, A., & Goswami, D. (2026) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.70021 · Cited by 3
Intranasal Nanoemulsion: A Promising Approach for the Management of Parkinson’s Disease
Jurel, P., Bahadur, S., & Bajpai, M. (2024) · Current Nanomaterials · doi:10.2174/0124054615343935240918053255 · Cited by 1
Application of Nanoemulsions in the Vaccination Process
Malik, S., Kishore, S., Kumar, S. A., Kumari, A., Kumari, M., & Dhasmana, A. (2021) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-7998-8378-4.ch022 · Cited by 1
Nose-to-Brain Drug Delivery Strategies for the Treatment of Neurological Disorders
Prabakaran, A., Bhatane, D., & Alexander, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_17 · Cited by 2
Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A Novel Approach to Diagnosis and Treatment
Khan, J., & Yadav, S. (2023) · Pharmaceutical Nanotechnology · doi:10.2174/0122117385265554230919070402 · Cited by 3
Development of lipid- and polymer-based nanocarriers for intranasal application
Akel, H. (2022) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11343 · Cited by 4
An, J., Li, X., Li, Z., Wang, J., & Pan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04417-y · Cited by 5
NANOTECHNOLOGY-DRIVEN THERAPEUTICS: ENHANCING BRAIN DRUG DELIVERY VIA NASAL PATHWAYS
Kumar, P., Verma, S., Singh, A., & Parashar, T. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i2.52879 · Cited by 4
Sarwal, A., Singh, G., Prasad, P., Sharma, S., & Ali, W. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_9 · Cited by 2
Potential theranostic targets in glioblastoma
Dabiri, S. M. H., Walsh, T., Behrooz, A. B., Yathindranath, V., Clark, C. J., Aghajani, S., Ahmadi, M., Madrakian, T., Miller, D. W., & Ghavami, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99873-4.00019-0 · Cited by 2
Asif, T. A., Ji, P., Qiao, X., Yang, Q., Jiang, D., & Zhang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805229 · Cited by 1
Application of Nanophytomedicine for the Treatment of Central Nervous System Disorders
Rarokar, N. R., Gurav, N. S., & Gurav, S. S. (2023) · Wiley eBooks · doi:10.1002/9781119794127.ch18 · Cited by 2
Kaempferol: Topical Applications and Nanoformulations in the Treatment of Diseases
Preeti, P., Akhtar, J., Verma, A., Badruddeen, B., Khan, M. I., & Ahmad, M. (2023) · Current Bioactive Compounds · doi:10.2174/1573407219666230418121102 · Cited by 2
Nose to Brain Drug Delivery for the Treatment of Epilepsy
Pratishtha, Srivastava, S., & Gupta, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_8 · Cited by 2
Phytochemical-based Nanoformulations for Drug-resistant Brain Cancer
Saini, N., Bhatt, S., & Kumar, M. (2023) · Nanoscience & Nanotechnology-Asia · doi:10.2174/2210681213666230609152755 · Cited by 1
Bhatt, P., Bhatt, T., Jain, V. K., Jain, R., & Bigoniya, P. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.154558 · Cited by 4
Krajišnik, D. R., Milić, J., Nikolić, I., & Savic, S. D. (2019) · Arhiv za farmaciju · doi:10.5937/arhfarm1906420k · Cited by 1
Shaghlil, L., Al‐Ebini, Y., Shawabkeh, M. J. A., Adam, F., Saxena, K. K., Alshishani, A., & Harun, W. S. W. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070902 · Cited by 3
Sonvico, F., Bazzo, G. C., & Stulzer, H. K. (2025) · Neuromethods · doi:10.1007/978-1-0716-4474-4_9 · Cited by 1
Prasher, P., Sharma, M., Fatima, R., Chugh, S., Mudila, H., Zacconi, F. C. M., Singh, S. K., Călina, D. C., Sharifi‐Rad, J., & Setzer, W. N. (2026) · Journal of Microencapsulation · doi:10.1080/02652048.2026.2676313 · Cited by 2
Das, S., Sarkar, M., Bagchi, A., & Bahadur, S. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02054-4 · Cited by 1
Applications of Minimally Invasive Drug Delivery Systems
Patil, L. N., Harish, V., Babu, M. R., & Srivastav, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-6275-3_11
Khatiwara, D., Sarma, S., Pathak, M., Sangroula, S., Sahariah, B. J., Deka, M. K., & Das, A. K. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06218-8
Advantages of Nasal Drug Delivery System
Sakhare, M. S. U., & Solanki, M. V. S. (2024) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-22672
HS15-based nanotherapeutics for direct nose-to-brain delivery against central nervous system fungal
Zhang, G., Ji, X., Zhang, W., & Mao, Y. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104232
Vasandia, A. V., More, M. P., Bhatt, P., Baheti, A., Pawar, A., & Tagalpallewar, A. A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108179 · Cited by 1
Yoshitaka, K., & Toorisaka, E. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107879
ELTAHAN, M., Baker, D. H. A., Abbas, H. S., Abdelmonem, R., El-Nabarawi, M. A., & Attia, A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i5.54735
Gebreel, R. M., Attia, A., Abdellatif, M. M., Al‐Gahtany, M., Ebrahim, H. A., & Shoman, N. A. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2619917
Tian, Q., Li, J., Cui, C., Zhou, G., Wang, Y., Sun, B., & Xia, Z. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4899275
Huang, Q., Zuo, Y., Xie, Y., Liu, Z., Wang, L., Xu, H., Yu, M., & Liu, C. (2026) · Biomaterials Science · doi:10.1039/d6bm00624h
Plant polysaccharides for nasal drug delivery
Necolau, M. I., Pandele, A. M., & Voicu, Ș. I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90780-4.00008-5
Intranasal Drug Delivery for CNS Diseases: Challenges, Advances, and Future Directions
Chouhan, S. S., Parashar, A. K., Mahajan, T., Sharma, Y., & Saraogi, G. K. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00477-8
Desarrollo y evaluación clínica de una formulación intranasal de butorfanol para uso en equinos
Velloso, M. I. (2023) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/152394
Rajesh, A., Subramony, A., Kumaar, R. N., Kumar, S. S., Biju, A., & Nair, S. S. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2682487
Nanoemulsions in brain targeting
Patel, H., Rathod, D., Panchal, P., & Patel, K. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36453-2.00016-1
Sharma, R., Monika, Tyagi, B., Gupta, D., Mazumder, R., & Mazumder, A. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249329586240924105624 · Cited by 1
Intranasal Drug Delivery in Treating Alzheimer’s Disease
Kumar, N., Nivatya, H. K., Singh, A. K., Sonam, Sharma, L., & Singh, V. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010015
Young, W., & Speight, M. O. (2021) · Stem Cell & Regenerative Medicine · doi:10.33425/2639-9512.1061 · Cited by 9
Intranasal Administration for Targeting Neurodegenerative Disorders
Tripathi, S. M., Mishra, S. K., Malviya, R., & Ojha, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324846125010006
Dama, D. S., Mannur, V. S., & Koli, R. (2026) · BioNanoScience · doi:10.1007/s12668-026-02540-6 · Cited by 2
Mucoadhesive chitosan-based drug carriers for local application
Paczkowska‐Walendowska, M., & Cielecka‐Piontek, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22151-4.00001-0 · Cited by 2
Kim, Y. B., Yun, C.-O., & Yoon, A. R. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2738285
Nanocarriers as an Emerging Tool for Drug Delivery to Combat Neurodegenerative Diseases
Sharma, P., & Singh, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_1 · Cited by 1
Crespo-Moral, M. (2022) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/55126
Nanotechnology and Secondary Metabolites: A Synergistic Approach to Combat Neurodegeneration
Kotha, K. K., Chandrakala, A. N., Kumarachari, R. K., Bukke, S. P. N., Sarangapani, P., & Karpagavalli, L. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-1365-8.ch012
USE OF NANOPARTICLES AND NANOMATERIALS TO INCREASE THE EFFICACY OF VACCINE PREPARATIONS
Berezin, V. E., Bogoyavlensky, A. P., Alexyuk, P., ZAYTSEVA, I. A., Omirtaeva, E. S., & Azizan, A. (2025) · МИКРОБИОЛОГИЯ ЖӘНЕ ВИРУСОЛОГИЯ · doi:10.53729/mv-as.2025.04.05
Hussain, A., Alnemer, O. A., & Altamimi, M. A. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03282-6
Indoria, S., Bala, M., & Singh, V. (2022) · Materials horizons · doi:10.1007/978-981-16-7483-9_3
Islamie, R., & Rodsiri, R. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.301
Cama, E. S., Botti, G., Perteghella, S., Catenacci, L., Tareen, F. K., Beggiato, S., Bonferoni, M. C., Ferraro, L., Sorrenti, M., & Dalpiaz, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091168
Self-citationAn Overview on Nanocarriers for Nasal Delivery
Dahiya, S., & Dahiya, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-23112-4_9 · Cited by 3
An overview of intranasal drug delivery systems for Alzheimer’s disease
Unnissa, Z., Unissa, M., Hussain, M. M., & Ali, S. S. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20253380
Liquid–Liquid Colloidal Systems as Advanced Biomedical Nanocarriers
Peula-García, J. M., Vicario‐de‐la‐Torre, M., & Esquena, J. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837675203-00391
T., N., DHARA, S., MANNA, P., & Kayal, P. (2026) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i1.56603 · Cited by 4
Theranostic applications in multiple sclerosis: Nanomedicines through nasal route
Kumar, R., Kunal, K., Sharma, A. B., Wadhwa, S., & Gulati, M. (2023) · AIP conference proceedings · doi:10.1063/5.0164748
Nanoparticles Administered through Nasal Cavity and Its Progress in the Treatment of Brain Diseases
邓, 爱. (2021) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2021.112010
Umeyor, C. E., Nayak, A., Kolekar, P., Mishra, G., Patankar, S., Vaidya, V. A., Suryavanshi, S., Sharma, S., & Patravale, V. B. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108575
Preparation and in vitro Immunoreactivity of Rosa rugosa Polysaccharide Liposomes
He, Q., Cheng, R., Shi, J., Na, T., Wang, Q., & Ochir, S. (2025) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-161557
Metadata
- Authors
- Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P.
- Affiliations
- University of Pavia (IT)
- University of Sassari (IT)
- Corresponding author
- Bonferoni, Maria Cristina
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2019-02-17
- Volume
- 11
- Issue
- 2
- Pages
- 84
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC6409749
- OpenAlex
- W2913486029
- Semantic Scholar
- a358c754a47e8059a8f72dc1342873a696c75c0c
- Cited by
- 269
- References
- 87
- Citations by year
- 2026: 29 · 2025: 36 · 2024: 29 · 2023: 53 · 2022: 47 · 2021: 33 · 2020: 33 · 2019: 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- nanoemulsions, nose-to-brain delivery, blood-brain barrier, intranasal drug delivery, olfactory nerve, trigeminal nerve, surfactants, neurological disorders, brain targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

